Equities

SeQuent Scientific Ltd

SEQUENT:NSI

SeQuent Scientific Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)173.44
  • Today's Change1.64 / 0.95%
  • Shares traded1.22m
  • 1 Year change+93.90%
  • Beta0.5541
Data delayed at least 15 minutes, as of Sep 20 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments688416591
Total Receivables, Net3,7543,7793,624
Total Inventory3,5303,5293,531
Prepaid expenses676259
Other current assets, total18911426
Total current assets8,2297,8997,832
Property, plant & equipment, net3,1123,5213,263
Goodwill, net2,3492,4001,808
Intangibles, net617684690
Long term investments8.9371439
Note receivable - long term169161142
Other long term assets1239237
Total assets15,40415,29114,510
LIABILITIES
Accounts payable2,6032,4432,580
Accrued expenses9.955.646.18
Notes payable/short-term debt2,4591,8211,595
Current portion long-term debt/capital leases700417411
Other current liabilities, total499573529
Total current liabilities6,2705,2615,121
Total long term debt1,7182,1981,643
Total debt4,8774,4363,649
Deferred income tax69123158
Minority interest564504480
Other liabilities, total217218187
Total liabilities8,8388,3037,589
SHAREHOLDERS EQUITY
Common stock499499497
Additional paid-in capital9,0039,0038,834
Retained earnings (accumulated deficit)1,2271,2551,144
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4937)(4332)(3933)
Total equity6,5666,9886,921
Total liabilities & shareholders' equity15,40415,29114,510
Total common shares outstanding249249248
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.